211 related articles for article (PubMed ID: 8404307)
1. [Pharmacokinetics study of intraperitoneal cisplatin in ovarian carcinoma].
Han GR; Cai GF
Zhonghua Fu Chan Ke Za Zhi; 1993 Apr; 28(4):224-6, 254. PubMed ID: 8404307
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
Deng C; Huang R; Lian L
Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
[TBL] [Abstract][Full Text] [Related]
3. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route.
Casper ES; Kelsen DP; Alcock NW; Lewis JL
Cancer Treat Rep; 1983 Mar; 67(3):235-8. PubMed ID: 6682012
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma.
Pretorius RG; Hacker NF; Berek JS; Ford LC; Hoeschele JD; Butler TA; Lagasse LD
Cancer Treat Rep; 1983 Dec; 67(12):1085-92. PubMed ID: 6228294
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
[TBL] [Abstract][Full Text] [Related]
6. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics study of intraperitoneal carboplatin in gynecologic carcinoma].
Tu C; Meng Y; Yang X
Zhonghua Fu Chan Ke Za Zhi; 1995 Apr; 30(4):212-4. PubMed ID: 7664606
[TBL] [Abstract][Full Text] [Related]
8. Regional pharmacokinetic selectivity of intraperitoneal cisplatin in ovarian cancer.
Esposito M; Campora E; Repetto M; Fulco RA; Simoni GA; Falcone A; Collecchi P; Gogioso L; Nobile MT; Civalleri D
Oncology; 1988; 45(2):69-73. PubMed ID: 3353075
[TBL] [Abstract][Full Text] [Related]
9. [Intraperitoneal chemotherapy for ovarian adenocarcinoma: pharmacokinetics of cisplatin].
Ravina JH; Szyller A; Mintz P; Ferrand S; Ciraru-Vigneron N; Zylberberg B; Bourdon R; Galliot M
J Gynecol Obstet Biol Reprod (Paris); 1992; 21(2):193-7. PubMed ID: 1583298
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetics of cisplatin in long-term hemodialysis treatment].
Sturn W; Sanwald R; Ehninger G
Dtsch Med Wochenschr; 1989 Mar; 114(9):337-9. PubMed ID: 2920679
[TBL] [Abstract][Full Text] [Related]
11. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer.
Sugiyama T; Kumagai S; Nishida T; Ushijima K; Matsuo T; Yakushiji M; Hyon SH; Ikada Y
Anticancer Res; 1998; 18(4B):2837-42. PubMed ID: 9713471
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of platinum in cancer patients treated with cisplatin at different doses.
Fracasso ME; Apostoli P; Benoni G; Bonetti A; Griso C; Leone R
Drugs Exp Clin Res; 1987; 13(6):367-72. PubMed ID: 3652926
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic study of intralesional cisplatin for the treatment of hepatocellular carcinoma.
Mok TS; Kanekal S; Lin XR; Leung TW; Chan AT; Yeo W; Yu S; Chak K; Leavitt R; Johnson P
Cancer; 2001 Jun; 91(12):2369-77. PubMed ID: 11413527
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of carboplatin after i.v. administration.
Elferink F; van der Vijgh WJ; Klein I; Vermorken JB; Gall HE; Pinedo HM
Cancer Treat Rep; 1987 Dec; 71(12):1231-7. PubMed ID: 3319135
[TBL] [Abstract][Full Text] [Related]
15. [Intraperitoneal high-dose cisplatinum chemotherapy (CDDP-ip) in patients with carcinomatous peritonitis].
Noda T; Oku M; Kiyozuka Y; Ninomiya Y; Hino K; Okamura Y; Maruyama M; Ichijo M
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1025-32. PubMed ID: 3566301
[TBL] [Abstract][Full Text] [Related]
16. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E
Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050
[TBL] [Abstract][Full Text] [Related]
17. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
Royer B; Delroeux D; Guardiola E; Combe M; Hoizey G; Montange D; Kantelip JP; Chauffert B; Heyd B; Pivot X
Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
[TBL] [Abstract][Full Text] [Related]
18. Plasma and tumor concentrations of cisplatin following intraperitoneal infusion or bolus injection with or without continuous low-dose-rate irradiation.
Fu KK; DeGregorio MW; Phillips JW
NCI Monogr; 1988; (6):123-7. PubMed ID: 3281027
[TBL] [Abstract][Full Text] [Related]
19. [Intraperitoneal chemotherapy of CDDP and etoposide in patients with advanced ovarian cancer].
Hirashima Y; Shimura T; Tanaka Y; Demukai H; Kubota T; Kobayashi T; Suzuki A
Gan To Kagaku Ryoho; 1993 Aug; 20(10):1321-6. PubMed ID: 8346930
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology of intraperitoneal cisplatin.
Lopez JA; Krikorian JG; Reich SD; Smyth RD; Lee FH; Issell BF
Gynecol Oncol; 1985 Jan; 20(1):1-9. PubMed ID: 4038390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
